Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
105last 24h
3126last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Investor's Business Daily93d agobullish
Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish VolumeSimply Wall St.110d agoneutral
Did Halozyme’s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine?Pharmaceutical Technology110d agoneutral
Halozyme and Incyte sign licence agreement for INCA033989 formulationsInvestorsHub111d agoneutral
Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 DevelopmentInsider Monkey116d agoneutral
Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer TreatmentSimply Wall St.157d agoneutral
How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment StoryInvesting.com164d agoneutral
JPMorgan says large-cap biotech is back as profits and pipelines fuel upsideSimply Wall St.166d agoneutral
Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns